Lineage Cell Therapeutics, Inc. (TLV:LCTX)
Israel · Delayed Price · Currency is ILS · Price in ILA 559.40
0.00 (0.00%)
Nov 27, 2025, 5:24 PM IDT
Lineage Cell Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 10.82 | 9.5 | 8.95 | 14.7 | 4.34 | 1.83 | Upgrade | |
Revenue Growth (YoY) | 24.05% | 6.19% | -39.16% | 238.70% | 137.73% | -48.05% | Upgrade |
Cost of Revenue | 12.76 | 12.81 | 16.38 | 0.73 | 1.43 | 0.39 | Upgrade |
Gross Profit | -1.95 | -3.31 | -7.43 | 13.98 | 2.92 | 1.44 | Upgrade |
Selling, General & Admin | 18.01 | 18.17 | 13.77 | 22.51 | 18.21 | 15.57 | Upgrade |
Research & Development | 0.39 | - | - | 13.99 | 33.91 | 12.32 | Upgrade |
Operating Expenses | 18.4 | 18.17 | 13.77 | 36.5 | 52.13 | 27.89 | Upgrade |
Operating Income | -20.34 | -21.48 | -21.2 | -22.52 | -49.21 | -26.45 | Upgrade |
Interest & Investment Income | 1.69 | 1.72 | 1.63 | 0.83 | 0 | 1.04 | Upgrade |
Currency Exchange Gain (Loss) | 1.38 | -0.57 | -1.04 | -2 | 1.49 | 2.88 | Upgrade |
Other Non Operating Income (Expenses) | -35.41 | 1.76 | 0.54 | 0.07 | 0.21 | -0.17 | Upgrade |
EBT Excluding Unusual Items | -52.68 | -18.57 | -20.08 | -23.62 | -47.52 | -22.7 | Upgrade |
Gain (Loss) on Sale of Investments | 0.01 | -0.01 | -0.18 | -2.19 | 3.73 | 0.78 | Upgrade |
Legal Settlements | - | - | -3.53 | - | - | - | Upgrade |
Other Unusual Items | - | - | 0.5 | - | 0.52 | - | Upgrade |
Pretax Income | -67.51 | -18.58 | -23.28 | -25.81 | -43.27 | -21.92 | Upgrade |
Income Tax Expense | - | - | -1.8 | 0.54 | - | -1.24 | Upgrade |
Earnings From Continuing Operations | -67.51 | -18.58 | -21.48 | -26.35 | -43.27 | -20.69 | Upgrade |
Minority Interest in Earnings | -0.15 | -0.03 | -0.01 | 0.08 | 0.25 | 0.04 | Upgrade |
Net Income | -67.66 | -18.61 | -21.49 | -26.27 | -43.02 | -20.65 | Upgrade |
Net Income to Common | -67.66 | -18.61 | -21.49 | -26.27 | -43.02 | -20.65 | Upgrade |
Shares Outstanding (Basic) | 231 | 200 | 173 | 170 | 165 | 150 | Upgrade |
Shares Outstanding (Diluted) | 231 | 200 | 173 | 170 | 165 | 150 | Upgrade |
Shares Change (YoY) | 25.54% | 15.94% | 1.69% | 3.22% | 9.64% | 3.10% | Upgrade |
EPS (Basic) | -0.29 | -0.09 | -0.12 | -0.15 | -0.26 | -0.14 | Upgrade |
EPS (Diluted) | -0.29 | -0.09 | -0.12 | -0.15 | -0.26 | -0.14 | Upgrade |
Free Cash Flow | -20.88 | -23.66 | -29.24 | 0.65 | -23.9 | -19.82 | Upgrade |
Free Cash Flow Per Share | -0.09 | -0.12 | -0.17 | 0.00 | -0.14 | -0.13 | Upgrade |
Gross Margin | -17.98% | -34.81% | -83.07% | 95.05% | 67.15% | 78.92% | Upgrade |
Operating Margin | -188.06% | -226.11% | -237.04% | -153.17% | -1133.63% | -1448.36% | Upgrade |
Profit Margin | -625.53% | -195.91% | -240.20% | -178.69% | -990.99% | -1130.83% | Upgrade |
Free Cash Flow Margin | -193.00% | -249.05% | -326.89% | 4.39% | -550.59% | -1085.27% | Upgrade |
EBITDA | -19.68 | -20.87 | -20.51 | -21.79 | -48.34 | -24.41 | Upgrade |
EBITDA Margin | -181.93% | -219.70% | -229.30% | -148.22% | - | - | Upgrade |
D&A For EBITDA | 0.66 | 0.61 | 0.69 | 0.73 | 0.87 | 2.04 | Upgrade |
EBIT | -20.34 | -21.48 | -21.2 | -22.52 | -49.21 | -26.45 | Upgrade |
EBIT Margin | -188.06% | -226.11% | -237.04% | -153.17% | - | - | Upgrade |
Revenue as Reported | 10.82 | 9.5 | 8.95 | 14.7 | 4.34 | 1.83 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.